Clinical characteristics of the t-AML cases in the 2 study cohorts
| Characteristic . | University of Chicago (n = 80) . | Washington University (n = 70) . |
|---|---|---|
| Sex, n (%) | ||
| Female | 44 (55) | 36 (51) |
| Male | 36 (45) | 34 (49) |
| Primary therapy, n (%) | ||
| Radiotherapy (RT) | 11 (14) | 7 (10) |
| Chemotherapy (CT) | 32 (40) | 23 (33) |
| Combined modality therapy (CMT) | 37 (46) | 40 (57) |
| Primary diagnosis, n (%) | ||
| Hematologic malignancies | 40 (50)* | 27 (39)† |
| Solid tumors | 38 (48)‡ | 36 (51)§ |
| Nonmalignant disorders | 2 (3)‖ | 7 (10)¶ |
| Therapy-related myeloid neoplasm, n (%) | ||
| t-AML | 62 (78) | 33 (47) |
| t-MDS | 18 (23) | 37 (53) |
| Cytogenetic features, n (%) | ||
| Loss of chromosome 5, 7, or both | 51 (65)# | 25 (36) |
| MLL or RUNX1 translocations | 9 (12) | 8 (11)** |
| Normal karyotype | 8 (10) | 12 (17) |
| Other karyotypes | 10 (13) | 25 (36) |
| Age at first cancer, y†† | 50 (7-85) | 51 (12-78) |
| Age at t-MDS/t-AML diagnosis, y†† | 59 (13-90) | 59 (19-87) |
| Latency, mo†† | 60.5 (11-639) | 56.4 (4-187) |
| Characteristic . | University of Chicago (n = 80) . | Washington University (n = 70) . |
|---|---|---|
| Sex, n (%) | ||
| Female | 44 (55) | 36 (51) |
| Male | 36 (45) | 34 (49) |
| Primary therapy, n (%) | ||
| Radiotherapy (RT) | 11 (14) | 7 (10) |
| Chemotherapy (CT) | 32 (40) | 23 (33) |
| Combined modality therapy (CMT) | 37 (46) | 40 (57) |
| Primary diagnosis, n (%) | ||
| Hematologic malignancies | 40 (50)* | 27 (39)† |
| Solid tumors | 38 (48)‡ | 36 (51)§ |
| Nonmalignant disorders | 2 (3)‖ | 7 (10)¶ |
| Therapy-related myeloid neoplasm, n (%) | ||
| t-AML | 62 (78) | 33 (47) |
| t-MDS | 18 (23) | 37 (53) |
| Cytogenetic features, n (%) | ||
| Loss of chromosome 5, 7, or both | 51 (65)# | 25 (36) |
| MLL or RUNX1 translocations | 9 (12) | 8 (11)** |
| Normal karyotype | 8 (10) | 12 (17) |
| Other karyotypes | 10 (13) | 25 (36) |
| Age at first cancer, y†† | 50 (7-85) | 51 (12-78) |
| Age at t-MDS/t-AML diagnosis, y†† | 59 (13-90) | 59 (19-87) |
| Latency, mo†† | 60.5 (11-639) | 56.4 (4-187) |
Non-Hodgkin lymphoma (n = 16), Hodgkin lymphoma (n = 14), nonmyeloid leukemia (n = 9), multiple myeloma (n = 1).
Non-Hodgkin lymphoma (n = 14), multiple myeloma (n = 6), Hodgkin lymphoma (n = 4), nonmyeloid leukemia (n = 3).
Includes cancers of the breast (n = 17), ovaries (n = 4), prostate (n = 3), cervix (n = 2), thyroid (n = 2), esophagus, head and neck, lung, rectum, stomach, testis, vulva, astrocytoma, sarcoma, and a primary site unknown.
Includes cancers of the breast (n = 18), rectum (n = 4), prostate (n = 2), uterus (n = 2), testis (n = 2), central nervous system (n = 2), thyroid, lung, head and neck, Ewing sarcoma, melanoma, and carcinoid.
Crohn disease (n = 2).
¶Multiple sclerosis (n = 3), scleroderma, rheumatoid arthritis, aplastic anemia, cyclic neutropenia.
Cytogenetic data available for 78 of 80 patients.
Fluorescence in situ hybridization for translocations was performed in 23 of 70 patients.
Values are median; minimum to maximum in parentheses.